FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895567013> ?p ?o ?g. }

• W2895567013 abstract "Abstract Background DAP is frequently employed in combination with a second antibiotic for enterococcal BSI. We previously observed that a free drug area under the curve to MIC ratio (fAUC/MIC) &gt;27.43 was predictive of survival when DAP was administered as monotherapy. The extent to which combination therapy affects DAP PD remains unexplored. Methods This study pooled data from 7 published trials assessing outcomes in DAP treated enterococcal BSI. fAUC/MIC was calculated using a published population pharmacokinetic model based on creatinine clearance, 90% protein binding, and baseline DAP MIC for each patient that received ≥72 hours of DAP as part of a combination antibiotic regimen. The fAUC/MIC threshold predictive of 30-day survival was determined by classification and regression tree analysis and confirmed by multivariable logistic regression. To control for comorbidities, the threshold was examined in the low-acuity patients only (APACHE-II score &lt;21, Charlson co-morbidity index &lt;5, or Pitt bacteremia score &lt;4). Monte Carlo simulation was performed to determine the probability of target attainment (PTA) over a range of MICs. Results In total, 240 adults were included and 137 (57.1%) were alive at 30 days. A majority of patients (62.8%) were immunosuppressed. Combination therapy with DAP plus a β-lactam was observed in 187 (77.9%) patients and with a β-lactam and 1 other active agent in 34 (14.2%) patients. Low-acuity patients (n = 135) were more likely to survive when fAUC/MIC &gt;12.3 was achieved (63.2% versus 20.0%, P = 0.015). This difference remained significant when controlling for BSI source and immunosuppression (P = 0.017). The PTA for a 6 mg/kg/day dose was 95.2% at MIC=2 mg/L and 43.0% at MIC=4 mg/L; PTA for a 12 mg/kg/day dose was 95.2% at 4 mg/L. Conclusion Compared with our previous observations for DAP monotherapy against enterococcal BSI, a lower DAP PD exposure was required when administered with at least one additional antibiotic. For combination therapy with DAP, a fAUC/MIC &gt;12.3 was associated with 30-day survival. As part of an active combination therapy regimen, DAP 6 mg/kg/day was appropriate for treatment of BSI caused by enterococci with MICs ≤2 mg/L, while 12 mg/kg/day was optimal for isolates with MICs of 4 mg/L. Disclosures J. L. Kuti, Merck & Co., Inc.: Consultant and Grant Investigator, Consulting fee and Research support. Pfizer, Inc.: Consultant, Consulting fee. Theravance Biopharma: Grant Investigator, Research support. Shionogi, Inc.: Grant Investigator, Research support. Allergan: Scientific Advisor and Speaker’s Bureau, Research support. C. Arias, Merck & Co., Inc.: Grant Investigator, Research support. MeMed: Grant Investigator, Research support. Allergan: Grant Investigator, Research support. N. S. Britt, Merck & Co., Inc.: Grant Investigator, Research support. Gilead Sciences, Inc.: Grant Investigator, Research support." @default.
• W2895567013 created "2018-10-12" @default.
• W2895567013 creator A5010659587 @default.
• W2895567013 creator A5037312576 @default.
• W2895567013 creator A5052605952 @default.
• W2895567013 creator A5053893299 @default.
• W2895567013 creator A5054034982 @default.
• W2895567013 creator A5058464996 @default.
• W2895567013 creator A5062115308 @default.
• W2895567013 creator A5074458877 @default.
• W2895567013 creator A5084829703 @default.
• W2895567013 creator A5088758954 @default.
• W2895567013 creator A5089030935 @default.
• W2895567013 creator A5090657231 @default.
• W2895567013 creator A5090740872 @default.
• W2895567013 creator A5091663701 @default.
• W2895567013 date "2018-11-01" @default.
• W2895567013 modified "2023-09-26" @default.
• W2895567013 title "1643. Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI)" @default.
• W2895567013 doi "https://doi.org/10.1093/ofid/ofy209.113" @default.
• W2895567013 hasPublicationYear "2018" @default.
• W2895567013 type Work @default.
• W2895567013 sameAs 2895567013 @default.
• W2895567013 citedByCount "0" @default.
• W2895567013 crossrefType "journal-article" @default.
• W2895567013 hasAuthorship W2895567013A5010659587 @default.
• W2895567013 hasAuthorship W2895567013A5037312576 @default.
• W2895567013 hasAuthorship W2895567013A5052605952 @default.
• W2895567013 hasAuthorship W2895567013A5053893299 @default.
• W2895567013 hasAuthorship W2895567013A5054034982 @default.
• W2895567013 hasAuthorship W2895567013A5058464996 @default.
• W2895567013 hasAuthorship W2895567013A5062115308 @default.
• W2895567013 hasAuthorship W2895567013A5074458877 @default.
• W2895567013 hasAuthorship W2895567013A5084829703 @default.
• W2895567013 hasAuthorship W2895567013A5088758954 @default.
• W2895567013 hasAuthorship W2895567013A5089030935 @default.
• W2895567013 hasAuthorship W2895567013A5090657231 @default.
• W2895567013 hasAuthorship W2895567013A5090740872 @default.
• W2895567013 hasAuthorship W2895567013A5091663701 @default.
• W2895567013 hasBestOaLocation W28955670131 @default.
• W2895567013 hasConcept C111113717 @default.
• W2895567013 hasConcept C112705442 @default.
• W2895567013 hasConcept C126322002 @default.
• W2895567013 hasConcept C151956035 @default.
• W2895567013 hasConcept C2776999253 @default.
• W2895567013 hasConcept C2778651397 @default.
• W2895567013 hasConcept C2778980435 @default.
• W2895567013 hasConcept C2779443120 @default.
• W2895567013 hasConcept C2779489039 @default.
• W2895567013 hasConcept C2781414143 @default.
• W2895567013 hasConcept C501593827 @default.
• W2895567013 hasConcept C523546767 @default.
• W2895567013 hasConcept C54355233 @default.
• W2895567013 hasConcept C71924100 @default.
• W2895567013 hasConcept C86803240 @default.
• W2895567013 hasConcept C89423630 @default.
• W2895567013 hasConceptScore W2895567013C111113717 @default.
• W2895567013 hasConceptScore W2895567013C112705442 @default.
• W2895567013 hasConceptScore W2895567013C126322002 @default.
• W2895567013 hasConceptScore W2895567013C151956035 @default.
• W2895567013 hasConceptScore W2895567013C2776999253 @default.
• W2895567013 hasConceptScore W2895567013C2778651397 @default.
• W2895567013 hasConceptScore W2895567013C2778980435 @default.
• W2895567013 hasConceptScore W2895567013C2779443120 @default.
• W2895567013 hasConceptScore W2895567013C2779489039 @default.
• W2895567013 hasConceptScore W2895567013C2781414143 @default.
• W2895567013 hasConceptScore W2895567013C501593827 @default.
• W2895567013 hasConceptScore W2895567013C523546767 @default.
• W2895567013 hasConceptScore W2895567013C54355233 @default.
• W2895567013 hasConceptScore W2895567013C71924100 @default.
• W2895567013 hasConceptScore W2895567013C86803240 @default.
• W2895567013 hasConceptScore W2895567013C89423630 @default.
• W2895567013 hasLocation W28955670131 @default.
• W2895567013 hasLocation W28955670132 @default.
• W2895567013 hasLocation W28955670133 @default.
• W2895567013 hasOpenAccess W2895567013 @default.
• W2895567013 hasPrimaryLocation W28955670131 @default.
• W2895567013 hasRelatedWork W2337699406 @default.
• W2895567013 hasRelatedWork W2342350918 @default.
• W2895567013 hasRelatedWork W2571169854 @default.
• W2895567013 hasRelatedWork W2582881339 @default.
• W2895567013 hasRelatedWork W2755716084 @default.
• W2895567013 hasRelatedWork W2783990215 @default.
• W2895567013 hasRelatedWork W2895567013 @default.
• W2895567013 hasRelatedWork W2899816146 @default.
• W2895567013 hasRelatedWork W2902821033 @default.
• W2895567013 hasRelatedWork W2954081200 @default.
• W2895567013 isParatext "false" @default.
• W2895567013 isRetracted "false" @default.
• W2895567013 magId "2895567013" @default.
• W2895567013 workType "article" @default.